FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:2375-2382 June 3, 2004 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the authors' clinical recommendations.

A 63-year-old man underwent complete resection of a T3N0M0, stage II adenocarcinoma of the ascending colon. No adjuvant therapy is planned. There is no family history of colorectal cancer. How should he be followed?

The Clinical Problem

Colorectal adenocarcinoma is the second leading cause of death due to cancer in the United States, accounting for more than 50,000 deaths annually.¹ Surgery is the cornerstone of . . . [Full Text of this Article]

Strategies and Evidence

Areas of Uncertainty

Specific Surveillance Tests

Other Uncertainties

Guidelines

Conclusions and Recommendations

Source Information

From the Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York (D.G.P.); the Division of Hematology–Oncology and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago (A.B.B.); and the Cancer Policy and Clinical Affairs Department, American Society of Clinical Oncology, Alexandria, Va. (M.R.S.).

Address reprint requests to Dr. Pfister at Memorial Hospital, Box 188, 1275 York Ave., New York, NY 10021, or at pfisterd@mskcc.org.

This article has been cited by other articles:

• Yang, W., Luo, D., Wang, S., Wang, R., Chen, R., Liu, Y., Zhu, T., Ma, X., Liu, R., Xu, G., Meng, L., Lu, Y., Zhou, J., Ma, D. (2008). TMTP1, a Novel Tumor-Homing Peptide Specifically Targeting Metastasis. Clin. Cancer Res. 14: 5494-5502 [Abstract] [Full Text]  
• Rodriguez-Moranta, F., Salo, J., Arcusa, A., Boadas, J., Pinol, V., Bessa, X., Batiste-Alentorn, E., Lacy, A. M., Delgado, S., Maurel, J., Pique, J. M., Castells, A. (2006). Postoperative Surveillance in Patients With Colorectal Cancer Who Have Undergone Curative Resection: A Prospective, Multicenter, Randomized, Controlled Trial. JCO 24: 386-393 [Abstract] [Full Text]  
• Goldberg, R. M. (2006). Intensive Surveillance After Stage II or III Colorectal Cancer: Is It Worth It?. JCO 24: 330-331 [Full Text]  
• Lee, J.-C., Lee, C.-H., Su, C.-L., Huang, C.-W., Liu, H.-S., Lin, C.-N., Won, S.-J. (2005). Justicidin A decreases the level of cytosolic Ku70 leading to apoptosis in human colorectal cancer cells. Carcinogenesis 26: 1716-1730 [Abstract] [Full Text]  
• Keating, N. L., Landrum, M. B., Meara, E., Ganz, P. A., Guadagnoli, E. (2005). Do Increases in the Market Share of Managed Care Influence Quality of Cancer Care in the Fee-For-Service Sector?. JNCI J Natl Cancer Inst 97: 257-264 [Abstract] [Full Text]